doi:10.1210/endo.141.11.7873
Claytons research contributions to PT-141 development include: Principal investigator for pivotal Phase 2 dose-finding trial establishing optimal 1.75 mg dose Lead investigator for RECONNECT Phase 3 trials supporting FDA approval Development of responder analysis methodology for patient-reported outcomes in sexual dysfunction Neurobehavioral research elucidating central mechanisms of sexual desire Extensive publication record on bremelanotide efficacy, safety, and clinical applications Her work has established PT-141 as the second FDA-approved pharmacological treatment for HSDD and the first melanocortin-based therapy for sexual dysfunction, representing a significant advance in womens sexual health treatment options
Fas-associated via death domain and TNFRSF1A associated via death domain (TRADD) facilitate the recruitment of initiator caspase 8 (CASP8) or caspase 10 (CASP10), resulting in the creation of a death-inducing signaling complex and subsequent activation of procaspase
When both operate simultaneously, you get appetite suppression from two independent mechanisms, enhanced fat oxidation from ketosis, improved insulin sensitivity from both pathways, and potentially better preservation of lean mass compared to either intervention alone
You can overconsume good calories, too
